Cosmological simulations of the formation of the stellar haloes around disc galaxies

We use the Galaxies-Intergalactic Medium Interaction Calculation (gimic) suite of cosmological hydrodynamical simulations to study the formation of stellar spheroids of Milky Way mass disc galaxies. The simulations contain accurate treatments of metal-dependent radiative cooling, star formation, supernova feedback and chemodynamics, and the large volumes that have been simulated yield an unprecedentedly large sample of ≈400 simulated ∼L* disc galaxies. The simulated galaxies are surrounded by low-mass, low surface brightness stellar haloes that extend out to ∼100 kpc and beyond. The diffuse stellar distributions bear a remarkable resemblance to those observed around the Milky Way, M31 and other nearby galaxies, in terms of mass density, surface brightness and metallicity profiles. We show that in situ star formation typically dominates the stellar spheroids by mass at radii of r≲ 30 kpc, whereas accretion of stars dominates at larger radii and this change in origin induces a change in the slope of the surface brightness and metallicity profiles, which is also present in the observational data. The system-to-system scatter in the in situ mass fractions of the spheroid, however, is large and spans over a factor of 4. Consequently, there is a large degree of scatter in the shape and normalization of the spheroid density profile within r≲ 30 kpc (e.g. when fitted by a spherical power-law profile, the indices range from −2.6 to −3.4). We show that the in situ mass fraction of the spheroid is linked to the formation epoch of the system. Dynamically, older systems have, on average, larger contributions from in situ star formation, although there is significant system-to-system scatter in this relationship. Thus, in situ star formation likely represents the solution to the long-standing failure of pure accretion-based models to reproduce the observed properties of the inner spheroid

Properties of galaxies reproduced by a hydrodynamic simulation.

Previous simulations of the growth of cosmic structures have broadly reproduced the 'cosmic web' of galaxies that we see in the Universe, but failed to create a mixed population of elliptical and spiral galaxies, because of numerical inaccuracies and incomplete physical models. Moreover, they were unable to track the small-scale evolution of gas and stars to the present epoch within a representative portion of the Universe. Here we report a simulation that starts 12 million years after the Big Bang, and traces 13 billion years of cosmic evolution with 12 billion resolution elements in a cube of 106.5 megaparsecs a side. It yields a reasonable population of ellipticals and spirals, reproduces the observed distribution of galaxies in clusters and characteristics of hydrogen on large scales, and at the same time matches the 'metal' and hydrogen content of galaxies on small scales

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p